TY - JOUR
T1 - Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women
T2 - JACC State-of-the-Art Review
AU - ACC CVD Womens Committee Members
AU - Cho, Leslie
AU - Davis, Melinda
AU - Elgendy, Islam
AU - Epps, Kelly
AU - Lindley, Kathryn J.
AU - Mehta, Puja K.
AU - Michos, Erin D.
AU - Minissian, Margo
AU - Pepine, Carl
AU - Vaccarino, Viola
AU - Volgman, Annabelle Santos
N1 - Funding Information:
Dr. Cho has received research support from Novartis; has received research support from and served as a consultant to Esperion and Amgen; and has served as a consultant to AstraZeneca. Dr. Minissian has served as a consultant for Amgen, Medtelligence, and the North American Center for Continuing Medical Education; and has received research support from the National Institutes of Health and NIHF. Dr. Pepine has received support from the NIH/NHLBI (WISE HFpEF, HL146158), NIH/NCATS (University of Florida Clinical and Translational Science, UL1TR001427), the Gatorade Trust through the University of Florida Department of Medicine, the McJunkin Family Foundation, and the U.S. Department of Defense (WARRIOR, PR161603). Dr. Vogelman has served as a consultant for the American Heart Association; and has served as a speaker for Aptus Health. All other authors have reported that they have no relationships relevant to the contents of this paper.
Publisher Copyright:
© 2020 American College of Cardiology Foundation
PY - 2020/5/26
Y1 - 2020/5/26
N2 - Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality for women in the United States and worldwide. There has been no American College of Cardiology (ACC)/American Heart Association guideline update specifically for the prevention of CVD in women since 2011. Since then, the body of sex-specific data has grown, in addition to updated hypertension, cholesterol, diabetes, atrial fibrillation, and primary prevention guidelines. The ACC CVD in Women Committee undertook a review of the recent guidelines and major studies to summarize recommendations pertinent to women. In this update, the authors address special topics, particularly the risk factors and treatments that have led to some controversies and confusion. Specifically, sex-related risk factors, hypertension, diabetes, hyperlipidemia, anticoagulation for atrial fibrillation, use of aspirin, perimenopausal hormone therapy, and psychosocial issues are highlighted.
AB - Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality for women in the United States and worldwide. There has been no American College of Cardiology (ACC)/American Heart Association guideline update specifically for the prevention of CVD in women since 2011. Since then, the body of sex-specific data has grown, in addition to updated hypertension, cholesterol, diabetes, atrial fibrillation, and primary prevention guidelines. The ACC CVD in Women Committee undertook a review of the recent guidelines and major studies to summarize recommendations pertinent to women. In this update, the authors address special topics, particularly the risk factors and treatments that have led to some controversies and confusion. Specifically, sex-related risk factors, hypertension, diabetes, hyperlipidemia, anticoagulation for atrial fibrillation, use of aspirin, perimenopausal hormone therapy, and psychosocial issues are highlighted.
KW - adverse pregnancy outcomes
KW - aspirin
KW - atrial fibrillation
KW - cardiovascular disease
KW - gestational diabetes
UR - http://www.scopus.com/inward/record.url?scp=85084392330&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85084392330&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2020.03.060
DO - 10.1016/j.jacc.2020.03.060
M3 - Review article
C2 - 32439010
AN - SCOPUS:85084392330
SN - 0735-1097
VL - 75
SP - 2602
EP - 2618
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 20
ER -